|
|
Post by sportsrancho on Jan 21, 2019 20:22:13 GMT -5
I was there with you guys of course, accurately stated. I was there with you guys and agree well said. The entire exec team waxed eloquent on the current state and plans for remainder of 2018. Suffice it to say those comments haven’t aged well. Especially Dr. K’s detailed remarks on lack of competition for ten years, publishing data from the veins of gold and the infamous SoC projection. With the countless commercial and financial blunders, it was so refreshing to see the Med Affairs function being led by a diabetes industry expert. For this year’s ASM, let’s take a look at the body of work done by Med Affairs since Dr. Kendall’s hiring. After we discuss the bloated top heavy organization of course. Yes, completely agree, and as stated a couple posts above you..it’s time for the no spin zone. |
|
|
|
Post by agedhippie on Jan 21, 2019 20:57:38 GMT -5
I hope his comment about no competition for ten years still holds true? I think that is somewhat optimistic. Micro-particle delivery is not exactly an understudied area, the barrier is the time to get it to approval. If the insulin big pharmas thought this was a threat they would just throw money at the problem much as they when Exubera looked like a threat. Nobody wants to be the one that has to educate the market, far easier to be a fast follower. |
|
|
|
Post by sayhey24 on Jan 21, 2019 21:06:28 GMT -5
I hope his comment about no competition for ten years still holds true? I keep looking but I see nothing that can compete. Ten years may be an understatement. On the basal side the Novo top scientists said Tresiba is the best they can do. You will not be seeing much in the insulin space. How can you do better than mimicking a healthy pancreas? After an hour or if you need a little more, no problem - take another puff. The best they will do are better AI pump algorithms which are limited by subq insulin.
Dr. Kendall has said a lot including this is the easiest job he has ever had. The reality is he may have under estimated what he was up against. My hope is he is the unstoppable force which has met the immovable object that was.
Until he can get changes to the SOC, I am afraid the sales staff is up against the immovable object and the commercials will have little impact. PWDs will ask their doctor and the doctor will say NO afrezza for you.
The near term path to jump start afrezza sales is through dedicated clinics.
In the mean time we should be hearing on a number of studies in the T2 space. We have the Baltimore Study and One Drop study. The problem Dr. Kendall could be facing is properly timing things for ADA2019.
|
|
|
|
Post by goyocafe on Jan 21, 2019 21:17:43 GMT -5
I hope his comment about no competition for ten years still holds true? I keep looking but I see nothing that can compete. Ten years may be an understatement. On the basal side the Novo top scientists said Tresiba is the best they can do. You will not be seeing much in the insulin space. How can you do better than mimicking a healthy pancreas? After an hour or if you need a little more, no problem - take another puff. The best they will do are better AI pump algorithms which are limited by subq insulin.
Dr. Kendall has said a lot including this is the easiest job he has ever had. The reality is he may have under estimated what he was up against. My hope is he is the unstoppable force which has met the immovable object that was.
Until he can get changes to the SOC, I am afraid the sales staff is up against the immovable object and the commercials will have little impact. PWDs will ask their doctor and the doctor will say NO afrezza for you.
The near term path to jump start afrezza sales is through dedicated clinics.
In the mean time we should be hearing on a number of studies in the T2 space. We have the Baltimore Study and One Drop study. The problem Dr. Kendall could be facing is properly timing things for ADA2019.
I don’t think I can handle another “we’ll release this data at the next ADA conference”. We saw how well the last one went and what it gained by waiting. |
|
|
|
Post by brotherm1 on Jan 21, 2019 21:31:54 GMT -5
I hope his comment about no competition for ten years still holds true? I think that is somewhat optimistic. Micro-particle delivery is not exactly an understudied area, the barrier is the time to get it to approval. If the insulin big pharmas thought this was a threat they would just throw money at the problem much as they when Exubera looked like a threat. Nobody wants to be the one that has to educate the market, far easier to be a fast follower. Or much easier to buy the company once it appears it will be successful |
|
|
|
Post by harryx1 on Jan 21, 2019 23:18:26 GMT -5
Every time I see that commecial I see opportunity lost. IMHO as a retired advertising executive the "award winning" no matter how many times it is aired the current commercial still lacks the hook that would drive more PWD to demand a prescription. Mike mentioned that award to defend spending money to shoot a new one and get it approved. If he would only shoot a brief scene of an Afrezza user in a restaurant or similar social encounter using the the dreamboat and edit into the commercial, he would get that hook without the major expense of starting from scratch. You'll never see a PWD pulling out a pen in one of there ads. The Dream Boat would resonate with PWD that struggle with using a pen in public. The purpose of a commercial is raise awareness to the level of the viewer taking action. That action might only be for the viewer to seek more information where they would find more benefits. Once they reach that stage they search the internet or go directly to the advertiser's website. Once they have done their homework they become more empowered to confidently discuss using Afrezza with their often reluctant physician. C'mon Mike fix that dog. It may have won an award, but not the commensurate numbers of new Afrezza users for the expense. We aren't selling food, soft drinks or a day at the park. IMO we need a really catchy tune (for the targeted audience) that will snap people's heads toward the TV and then show several segments of people using Afrezza in real life situations like this... |
|
|
|
Post by agedhippie on Jan 22, 2019 9:24:33 GMT -5
Or much easier to buy the company once it appears it will be successful That too  |
|
|
|
Post by peppy on Jan 22, 2019 12:28:20 GMT -5
lunch time afrezza commercial MSNBC
|
|
|
|
Post by peppy on Jan 22, 2019 13:15:17 GMT -5
holy moly a second lunch time commercial MSNBC
(Nothing on Bloomberg) heh
|
|
|
|
Post by sportsrancho on Jan 22, 2019 14:13:48 GMT -5
ST...@rooksleanne ~~ hey.. Saw our tv commercial yesterday on WGN cable and Saturday on the history channel... Here's hoping we get some traction
|
|
|
|
Post by sportsrancho on Jan 22, 2019 15:24:26 GMT -5
ST...$MNKD Afrezza commercial on Hallmark Channel in SE Texas just now & has been on Fox the past few days. My sister checked in..😂🤣 Bullish
|
|
|
|
Post by peppy on Jan 22, 2019 17:30:01 GMT -5
4:30 central time, Afrezza commercial MSNBC. I have two flat screens in front of me, one on MSNBC, one on CNN I can not watch the third, I find myself wanting their heads to blow (out, off or up).  |
|
|
|
Post by sportsrancho on Jan 22, 2019 23:03:44 GMT -5
Big Cheeze...$MNKD 7:37pm Fox News Las Vegas commercial followed by 7:57 Toujeo(SNY) commercial🤔SNY is relentless...Afrezza will be BO candidate...cont.
|
|
|
|
Post by sportsrancho on Jan 22, 2019 23:08:42 GMT -5
Rick H.....$MNKD Afrezza Commercial Just on Fox News the Ingraham Angle👍 Excellent ❗️👌 Bullish
|
|
|
|
Post by peppy on Jan 22, 2019 23:52:35 GMT -5
Afrezza commercial MSNBC half way through, The 11th Hour.
|
|
